Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by westcoast1000on Nov 14, 2022 11:25am
293 Views
Post# 35096712

kol meeting

kol meetingI missed the first part and entered during a disussion of previous unsuccessful treatment regimes.

They turned to the Goblet trial and reviewed the data. Not a great deal that was new was stated. All the participants said that they would be able to recruit patients for a future large scale trial readily, although they would have to allow crossover because no one would want to be on the control arm. They stated that in their view the results seen so far would be considered very solid and a big improvement over SOC if they continue to be demonstrated in a large randomized trial. Finally they noted the complete response is a rare thing, but it was monitored and measured with imaging. They did not expect to see more frequent such responses in a larger tirail

They were all cautious in making statements. It seemed a very serious event.
<< Previous
Bullboard Posts
Next >>